Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Eledon Pharmaceuticals Inc
NASDAQ ELDN
Data sourced from
and
and
Eledon Pharmaceuticals Inc Interest Expense To Sales for the year ending December 31, 2023
Eledon Pharmaceuticals Inc Interest Expense To Sales is NA for the year ending December 31, 2023. The interest expense to sales ratio is a financial metric that represents the proportion of a company's revenue that is used to cover its interest expenses. It is calculated by dividing the company's interest expense by its total revenue. This ratio indicates the financial burden of interest payments on the company's operating income. A higher ratio suggests that a significant portion of the company's revenue is being used to service interest obligations, potentially affecting its profitability.
-
Eledon Pharmaceuticals Inc Interest Expense To Sales for the year ending December 31, 2021 was 168.33%, a -97.83% change year over year.
-
Eledon Pharmaceuticals Inc Interest Expense To Sales for the year ending December 31, 2020 was 7,761.67%.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ELDN
| CEO | Dr. David-Alexandre C. Gros M.D., Ph.D. |
| IPO Date | Sept. 17, 2014 |
| Location | United States |
| Headquarters | 19900 MacArthur Boulevard, Irvine, CA, United States, 92612 |
| Employees | 20 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Key trends
Similar companies
Day One Biopharmaceuticals Inc
NA
NA
Acumen Pharmaceuticals Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email